Rhode Island Hospital

60 Degrees Pharma's Tafenoquine Receives IRB Approval for Phase II Chronic Babesiosis Study

5 months ago

• 60 Degrees Pharmaceuticals has received IRB approval for a Phase II study evaluating Tafenoquine for chronic babesiosis. • The open-label study will assess the efficacy and safety of Tafenoquine over 90 days in patients with chronic babesiosis. • Patient enrollment is expected to commence in Q3 2025, targeting those with significant functional impairment for at least six months. • The company estimates a substantial addressable market for Tafenoquine in babesiosis, potentially exceeding 400,000 patients by 2035.

60 Degrees Pharma's Tafenoquine Study for Babesiosis in Immunocompromised Patients Gains IRB Approval

10 months ago

• 60 Degrees Pharma received IRB approval for an expanded access study of tafenoquine to treat persistent babesiosis in immunocompromised patients. • The study aims to validate an 80% cure rate observed in a previous Yale School of Public Health case series using tafenoquine. • Tafenoquine, approved for malaria prophylaxis as ARAKODA, is being investigated for a new indication to treat babesiosis. • The company plans to file an NDA with the FDA in Q2 2026 for tafenoquine as a treatment for babesiosis, targeting acute and chronic cases.